Novavax, Inc. (NVAX)
| Market Cap | 1.40B |
| Revenue (ttm) | 885.19M |
| Net Income (ttm) | -284.86M |
| Shares Out | 160.18M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,204 |
| Open | 8.75 |
| Previous Close | 8.63 |
| Day's Range | 8.70 - 8.92 |
| 52-Week Range | 3.53 - 23.86 |
| Beta | 2.04 |
| Analysts | Buy |
| Price Target | 17.83 (+104.47%) |
| Earnings Date | Nov 12, 2024 |
About NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n... [Read more]
Financial Performance
In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $17.83, which is an increase of 104.47% from the latest price.
News
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax...
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , ...
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology p...
Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX) Jefferies London Healthcare Results Conference November 20, 2024 6:00 AM ET Company Participants Jim Kelly - Executive Vice President, Chief Financial Officer and Treasure...
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department
Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md. , Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company gr...
Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select va...
Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic...
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate ...
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial c...
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Execut...
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax's stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
Novavax Inc.'s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue.
Novavax Stock Dives Even Though Results Beat Forecasts
The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared with the $74 million analysts expected.
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi.
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total revenue of $85 million in the thir...
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Novavax (NVAX) shares edged higher Monday after the drugmaker announced that federal regulators have given the company the go-ahead to continue testing its combination COVID-19-flu and standalone flu ...
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
GAITHERSBURG, Md. , Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Dr...
Novavax, UK terminate vaccine supply agreement
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency related to its COVID-19 vaccine supply agreement.
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
GAITHERSBURG, Md. , Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third q...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Novavax, Inc. (NVAX) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ:N...